deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT01069120

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304

Sponsor: Repros Therapeutics Inc.

Conditions Uterine Fibroids
Interventions Proellex
Updated 7 times since 2017 Last updated: Aug 5, 2014 Started: Apr 30, 2009 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Repros stopped study due to safety and FDA placed study on hold

Other terminated trials from Repros Therapeutics Inc.

More terminations from Repros Therapeutics Inc.

Other Uterine Fibroids trials with similar outcome

Browse all Uterine Fibroids trials

A PHASE3 clinical study on Uterine Fibroids, this trial is terminated or withdrawn. The trial is conducted by Repros Therapeutics Inc. and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Repros Therapeutics Inc.
Data source: Repros Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations